Literature DB >> 2840732

Treatment of two cases of cryptococcal meningitis with fluconazole.

J W van 't Wout1, E R de Graeff-Meeder, L C Paul, W Kuis, R van Furth.   

Abstract

Two patients with cryptococcal meningitis were treated with the investigational triazole drug fluconazole (UK-49,858). Cerebrospinal fluid (CSF) levels of fluconazole were between 3.0 and 5.4 mg/l 2 h after an oral dose of 50 mg daily in the first patient and between 7.9 and 9.0 mg/l after an oral dose of 100 mg daily in the second patient. These levels were in the same range as plasma levels. The first patient, a 46-year-old renal transplant patient, was both clinically and microbiologically cured after 28 weeks of therapy (follow-up 14 months). In the second patient, a 15-year-old girl with chronic mucocutaneous candidiasis, fluconazole led to clinical cure of the meningitis, but failed to eradicate cryptococci from the CSF. These cases illustrate that fluconazole is useful for the treatment of cryptococcal meningitis, especially when prolonged treatment is indicated as in patients with immunodeficiencies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840732     DOI: 10.3109/00365548809032437

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

Review 1.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  A homozygous CARD9 mutation in a family with susceptibility to fungal infections.

Authors:  Erik-Oliver Glocker; Andre Hennigs; Mohammad Nabavi; Alejandro A Schäffer; Cristina Woellner; Ulrich Salzer; Dietmar Pfeifer; Hendrik Veelken; Klaus Warnatz; Fariba Tahami; Sarah Jamal; Annabelle Manguiat; Nima Rezaei; Ali Akbar Amirzargar; Alessandro Plebani; Nicole Hannesschläger; Olaf Gross; Jürgen Ruland; Bodo Grimbacher
Journal:  N Engl J Med       Date:  2009-10-29       Impact factor: 91.245

Review 3.  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.

Authors:  F N Vincent-Ballereau; O N Patey; C Lafaix
Journal:  Pharm Weekbl Sci       Date:  1991-04-26

Review 4.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 5.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 6.  Safety of fluconazole in paediatrics: a systematic review.

Authors:  Oluwaseun Egunsola; Abiodun Adefurin; Apostolos Fakis; Evelyne Jacqz-Aigrain; Imti Choonara; Helen Sammons
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.